3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Perivascular Epithelioid Cell Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Histiocytoma, Angiomatoid Fibrous
1
Granuloma, Plasma Cell
1
Fibrosarcoma
1
Fallopian Tube Neoplasms
1
Dermatofibrosarcoma
1
Chondrosarcoma, Mesenchymal
1
Chondrosarcoma, Extraskeletal Myxoid
1
Carcinoma, Ovarian Epithelial
1
Interventions
Rituximab
2
loncastuximab tesirine
1
etoposide phosphate
1
blinatumomab
1
Tubercidin
1
Immunotherapy, Adoptive
1
Ifosfamide
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, B-Cell
×
Ifosfamide
×
Clear all
NCT05991388
2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3
Recruiting
210 enrolled